
Presenters at Psych Congress Share Clinical Tips, New Research
From addressing borderline personality disorder to preventing drug-drug interactions and more, Psych Congress faculty shared useful diagnostic and treatment information.
CONFERENCE REPORTER
From addressing borderline personality disorder to preventing drug-drug interactions and more, Psych Congress faculty shared useful diagnostic and treatment information. The featured speakers, which included Psychiatric Times’ Editorial Board members Phillip Resnick, MD, and Thomas Kosten, MD, discussed hot issues in psychiatry during the four-day conference.
Several sessions addressed the complexities of treating patients as well as new potential treatment options. For instance, Marlene Freeman, MD, Director of Clinical Services in the Perinatal and Reproductive Psychiatry Program at Massachusetts General Hospital, shared tips and insights for treating women of reproductive potential. One important point she impressed on attendees is balancing the risk of psychopharmacological agents with the risk associated with an untreated mental disorder. For instance, untreated antenatal depression is associated with the risk of low birth weight, prematurity, small gestational age, and neonatal behavioral differences (eg, irritability and decreased activity). Yet recent findings indicate the absolute risk of selective serotonin reuptake inhibitor exposure in pregnancy is small. Similarly, case-control studies have shown inconsistent data regarding teratogenic risk of SSRIs. Thus, for moderate-to-severe depression, Freeman suggested clinicians discuss the risks and benefits of antidepressants with mothers and, when warranted, use the lowest effective dose. She also emphasized that non-medication alternatives, such as psychotherapy, should be maximized.
On the opposite side of the spectrum, Rick Doblin, PhD, founder and executive director of the
MAPS concluded its Phase 2 trial of MDMA-assisted psychotherapy with positive results. They found that 56% of patients no longer met criteria for PTSD following the treatment, compared with 23% in the placebo group. Plus, the number grew over time for the MDMA group, with 68% no longer meeting criteria at 12-month follow-up. Building on this success, MAPS has initiated Phase 3 studies, with the hope of obtaining FDA approval for the treatment at the conclusion of these studies.
On the attention-deficit/hyperactivity disorder front, Timothy Wilens, MD, Chief of the Division of Child and Adolescent Psychiatry and Associate Professor of Psychiatry at
Now, the focus is on new pharmacological approaches to treating ADHD. Wilens noted a few drugs that are recently approved or in the later stages of study. For instance, dasotraline, which is a novel dual-acting dopamine and norepinephrine reuptake inhibitor, is in the registration phase with the FDA. Centanafadine, a triamine reuptake inhibitor that works with dopamine, serotonin, and norepinephrine, is in Phase 3 trials. Molindrone (SPN-810) is being studied to address impulsive aggressive behavior associated with ADHD; it is in Phase 3 trials. Another norepinephrine reuptake inhibitor, known as SPN-812, is in Phase 3 randomized control trials for ADHD in adolescents. Wilens also reported that the norepinephrine reuptake inhibitor
The editors at Psychiatric Times invited speakers to share
If you would like to learn more about these and other topics from
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.